近日，我所在Frontiers in Pharmacology的“Pharmacology of Autoimmune Disease”栏目在线发表了两篇原始研究论文：“CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-alpha signaling and comparative efficacy with biological agents”（共同第一作者：张凤，疏金玲）和“CP-25 attenuates the activation of CD4(+) T cells stimulated with immunoglobulin D in human”（共同第一作者：吴育晶，陈恒石）。研究发现了本所发明的新化合物CP-25对异常活化的人T淋巴细胞和B淋巴细胞功能的调节作用特点及可能机制，并首次在英文学术期刊中提出CP-25是有前景的抗炎免疫软调节药。

文章链接：

https://www.frontiersin.org/articles/10.3389/fphar.2017.00933/full

https://www.frontiersin.org/articles/10.3389/fphar.2018.00004/full